AllPennyStocks.com Citizens Says FDA’s 'Unexpected' Phase 3 Request Clouds Mirum’s Near-Term Outlook – MIRM Stock Crashes 15%
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Citizens Says FDA’s 'Unexpected' Phase 3 Request Clouds Mirum’s Near-Term Outlook – MIRM Stock Crashes 15%

The firm said the U.S. Food and Drug Administration’s request for an additional Phase 3 trial of Volixibat to treat a liver disease is expected to delay the program.

Other Penny Stock Movers

Casino Tables Are Going Social, and This Microcap Just Expanded Its Reach
This Mining Tech Play Wants to Turn Stranded Deposits Into Metal
Curaleaf Eyes Aurora Cannabis in Deal That Could Reshape the Global Cannabis Market
Most Popular
{{ index + 1 }}


Back to Top